Theriva Biologics, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Theriva Biologics sold its antibiotic-degrading enzyme portfolio (SYN-004/ribaxamase, SYN-007, SYN-006) to Canadian biotech Biossil Labs Inc. effective October 30, 2026. Theriva received $350,000 upfront, is eligible for up to $3M in regulatory milestones, up to $88M in sales milestones on cumulative net sales, and low single-digit royalties capped at $250M aggregate. Biossil assumes all development and commercialization costs. Additionally, Theriva amended a prior 2012 agreement with Prev ABR LLC: it must pay Prev ABR a $140K closing fee plus 50% of regulatory/sales milestones, 33.3% of royalties, and 50% of other consideration received, up to a $13M payment cap to Prev ABR.
Why this rating
Asset sale generates immediate $350K liquidity and defers future development costs for micro-cap ($3.9M) company, improving cash runway; however, sale divests revenue-generating potential and reduces upside. Terms appear reasonable given stage/risk. Material relative to company size but not transformational.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.